Dose-response relationship between sulfonylureas and major adverse cardiovascular events in elderly patients with type 2 diabetes

2016 ◽  
Vol 25 (10) ◽  
pp. 1186-1195 ◽  
Author(s):  
Ahmed S. Abdelmoneim ◽  
Dean T. Eurich ◽  
Ambikaipakan Senthilselvan ◽  
Weiyu Qiu ◽  
Scot H. Simpson
Keyword(s):  
Type 2 Diabetes ◽  
Elderly Patients ◽  
Dose Response ◽  
Cardiovascular Events ◽  
Major Adverse Cardiovascular Events ◽  
Response Relationship ◽  
Dose Response Relationship

Abstract P351: White Rice Consumption and Risk of Type 2 Diabetes: A Meta-analysis and Systematic Review

Circulation ◽  
2012 ◽  
Vol 125 (suppl_10) ◽  
Author(s):  
Emily A Hu ◽  
Qi Sun ◽  
An Pan ◽  
Vasanti Malik
Keyword(s):  
Type 2 Diabetes ◽  
Dose Response ◽  
Prospective Cohort ◽  
Meta Analysis ◽  
Response Relationship ◽  
Dose Response Relationship ◽  
White Rice ◽  
Prospective Cohort Studies ◽  
Rice Consumption

Objectives: To summarize evidence regarding the association between white rice consumption and risk of type 2 diabetes and to quantify the potential dose-response relationship. Design: Meta-analysis of prospective cohort studies. Data Sources: We searched MEDLINE and EMBASE databases for articles published through July 2011 using keywords that included both rice intake and diabetes. We further searched references of included original studies. Study Selection: Prospective cohort studies that reported risk estimates of type 2 diabetes by white rice intake levels were selected for inclusion. Data Synthesis: Relative risks were pooled using a fixed-effects model. We also modeled the dose-response relationship utilizing data from all white rice intake categories in each study. Results: We identified 4 articles that included 7 distinct prospective cohort analyses for this study. A total of 13,284 incident cases of type 2 diabetes were ascertained among 352,384 participants with follow-up periods ranging from 4 to 22 years. The pooled relative risk (RR) for type 2 diabetes was 1.21 (95% confidence interval [CI], 1.08-1.34) comparing the highest with the lowest category of white rice intake. In addition, the dose-response meta-analysis suggested a linear association between white rice consumption and risk of type 2 diabetes: the RR (95% CI) was 1.10 (1.07, 1.14; P <0.001) for each serving/d (∼158 grams for a serving of cooked rice) increased intake of white rice. Conclusion: Frequent consumption of white rice is associated with a moderately increased risk of type 2 diabetes. These findings support the recommendation that consumption of white rice should be reduced in place of healthier options such as brown rice and other whole grains to lower risk of diabetes.

scholarly journals Alendronate Use and Risk of Type 2 Diabetes: A Nationwide Danish Nested Case-Control Study

2021 ◽  
Vol 12 ◽  
Author(s):  
Rikke Viggers ◽  
Zheer Al-Mashhadi ◽  
Jakob Starup-Linde ◽  
Peter Vestergaard
Keyword(s):  
Type 2 Diabetes ◽  
Dose Response ◽  
Case Control Study ◽  
Case Control ◽  
Incidence Density ◽  
Response Relationship ◽  
Dose Response Relationship ◽  
Nested Case Control ◽  
Control Study

ObjectiveA link has been proposed between glucose homeostasis and bone metabolism. Bisphosphonates are first-line treatment of osteoporosis, and we aimed to investigate whether the risk of developing type 2 diabetes was associated with prior use of alendronate.Research Design and MethodsWe conducted a population-based nested case-control study through access to all discharge diagnoses (ICD-10 system) from the National Danish Patient Registry along with all redeemed drug prescriptions (ATC classification system) from the Health Service Prescription Registry. All cases with a diagnosis of type 2 diabetes between 2008 and 2018 were matched on sex and age with 3 randomly selected controls by incidence-density sampling. Exposure was defined as ever use of alendronate and further grouped as effective and compliant use. ORs were calculated by conditional logistic regression analysis with adjustment for several confounders and test for trend for dose-response relationship.ResultsWe included 163,588 patients with type 2 diabetes and 490,764 matched control subjects with a mean age of 67 years and 55% male subjects. The odds of developing type 2 diabetes were lower among ever users of alendronate (multiple adjusted OR: 0.64 [95% CI 0.62-0.66]). A test for trend suggested a dose-response relationship between longer effective use of alendronate and lower risk of type 2 diabetes.ConclusionThese results suggest a possible protective effect of alendronate in a dose-dependent manner against development of type 2 diabetes.

scholarly journals Association between Obstructive Sleep Apnea and Type 2 Diabetes Mellitus: A Dose-Response Meta-Analysis

2021 ◽  
Vol 2021 ◽  
pp. 1-14
Author(s):  
Zhixiang Yu ◽  
Jin-Xiang Cheng ◽  
Dong Zhang ◽  
Fu Yi ◽  
Qiuhe Ji
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Dose Response ◽  
Odds Ratio ◽  
Observational Studies ◽  
Meta Analysis ◽  
Response Relationship ◽  
Dose Response Relationship ◽  
Obstructive Sleep

Aim/Introduction. Obstructive sleep apnea (OSA) is a sleep-related breathing disorder that is characterized by repeated episodes of upper airway occlusion during sleep. The patients with OSA suffered from comprehensive oxidative stress in all systems. OSA might induce type 2 diabetes mellitus (T2DM), a kind of metabolism disorder. In this passage, we are exploring the dose-response relationship between OSA and T2DM. Materials and Methods. We screened four databases (PubMed, Embase, Cochran Library, and CNKI) for the observational studies about the OSA and T2DM. Studies were collected from database establishment to October 2020. We performed a traditional subgroup meta-analysis. What is more, linear and spline dose-response models were applied to assess the association between apnea-hypopnea index (AHI), an indicator to evaluate the severity of OSA, and the risk of T2DM. Review Manager, version 5.3, software and Stata 16.0 were used for the analysis. Result. Seven observational studies were included in the research. We excluded a study in the conventional meta-analysis. In the subgroup analysis, mild-dose AHI increased the risk of T2DM (odds ratio = 1.23, 95% confidence interval = 1.06–1.41, P  < 0.05). Moderate-dose AHI increased the risk of T2DM with a higher odds ratio (OR = 1.35, 95% CI = 1.13–1.61, P  < 0.05). Moderate-to-severe-dose AHI increased the risk of T2DM with a higher odds ratio (OR = 2.14, 95% CI = 1.72–2.67, P  < 0.05). Severe-dose AHI increased the risk of T2DM with a higher odds ratio (OR = 2.19 95% CI = 1.30–3.68, P  < 0.05). Furthermore, the spline and linear dose-response meta-analysis results revealed that the risk of T2DM increased with increasing AHI values. Conclusion. Through the dose-response meta-analysis, we found a potential dose-response relationship existed between the severity of OSA and the risk of T2DM. This relationship in our passage should be considered in the prevention of T2DM in the future.

Pharmacokinetics, Pharmacodynamics, and Dose-Response Relationship of Repaglinide in Type 2 Diabetes

1999 ◽  
Vol 1 (3) ◽  
pp. 247-256 ◽  
Author(s):  
Poul Strange ◽  
Sherwyn L. Schwartz ◽  
Ronald J. Graf ◽  
William Polvino ◽  
Irving Weston ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Dose Response ◽  
Response Relationship ◽  
Dose Response Relationship ◽  
Relationship Of

scholarly journals Heterogeneity of antidiabetic treatment effect on the risk of major adverse cardiovascular events in type 2 diabetes: a systematic review and meta-analysis

2020 ◽  
Vol 19 (1) ◽  
Author(s):  
Elvira D’Andrea ◽  
Aaron S. Kesselheim ◽  
Jessica M. Franklin ◽  
Emily H. Jung ◽  
Spencer Phillips Hey ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Cardiovascular Disease ◽  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Treatment Effect ◽  
Cardiovascular Events ◽  
Major Adverse Cardiovascular Events ◽  
Uncontrolled Diabetes ◽  
History Of

Abstract Background We explored whether clinically relevant baseline characteristics of patients with type 2 diabetes can modify the effect of glucagon-like peptide-1 receptor agonists (GLP-1 RA) or sodium-glucose cotransporter-2 inhibitors (SGLT-2i) on the risk of major adverse cardiovascular events (MACE). Methods We investigated Medline and EMBASE through June 2019. We included randomized clinical trials reporting the effect of GLP-1 RA or SGLT-2i on MACE in subgroups of patients with type 2 diabetes, identified through key baseline factors: established cardiovascular disease; heart failure; chronic kidney disease; uncontrolled diabetes; duration of diabetes; hypertension; obesity; age; gender and race. Hazard ratios (HRs) and 95% confidence intervals (CIs) from trials were meta-analyzed using random-effects models. Results Ten trials enrolling 89,790 patients were included in the analyses. Subgroup meta-analyses showed a 14% risk reduction of MACE in patients with established cardiovascular disease [GLP1-RA: HR, 0.86 (95% CI, 0.80–0.93); SGLT-2i: 0.86 (0.80–0.93)], and no effect in at-risk patients without history of cardiovascular events [GLP1-RA: 0.94 (0.82–1.07); SGLT-2i: 1.00 (0.87–1.16)]. We observed a trend toward larger treatment benefits with SGLT-2i among patients with chronic kidney disease [0.82 (0.69–0.97)], and patients with uncontrolled diabetes for both GLP1-RA or SGLT-2i [GLP1-RA: 0.82 (0.71–0.95); SGLT-2i: 0.84 (0.75–0.95)]. Uncontrolled hypertension, obesity, gender, age and race did not appear to modify the effect of these drugs. Conclusions In this exploratory analysis, history of cardiovascular disease appeared to modify the treatment effect of SGLT2i or GLP1-RA on MACE. Chronic kidney disease and uncontrolled diabetes should be further investigated as potential effect modifiers.

Sign in / Sign up

Export Citation Format

Share Document